MCID: THR024
MIFTS: 56

Thrombosis

Categories: Blood diseases, Cardiovascular diseases

Aliases & Classifications for Thrombosis

MalaCards integrated aliases for Thrombosis:

Name: Thrombosis 12 29 54 44 15 70
Thrombosis of Blood Vessel 70

Classifications:



External Ids:

Disease Ontology 12 DOID:0060903
MeSH 44 D013927
UMLS 70 C0040053 C2586211

Summaries for Thrombosis

Disease Ontology : 12 A vascular disease caused by the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system.

MalaCards based summary : Thrombosis, also known as thrombosis of blood vessel, is related to cavernous sinus thrombosis and portal vein thrombosis. An important gene associated with Thrombosis is SERPINC1 (Serpin Family C Member 1), and among its related pathways/superpathways are Collagen chain trimerization and Response to elevated platelet cytosolic Ca2+. The drugs Norethindrone and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include endothelial, kidney and liver, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 73 Thrombosis (from Ancient Greek θρόμβωσις thrómbōsis "clotting”) is the formation of a blood clot inside... more...

Related Diseases for Thrombosis

Diseases related to Thrombosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2097)
# Related Disease Score Top Affiliating Genes
1 cavernous sinus thrombosis 33.1 SERPINC1 F3 F2
2 portal vein thrombosis 33.0 SERPINE1 SERPINC1 PROC PLAT JAK2 F5
3 thrombophilia due to thrombin defect 32.9 THBD SERPINE1 SERPINC1 PROC PLAT F5
4 coronary thrombosis 32.9 SERPINE1 SERPINC1 PLG PLAT GP1BA F3
5 lateral sinus thrombosis 32.8 SERPINC1 F2
6 intracranial thrombosis 32.8 SERPINC1 PLG PLAT GP1BA F5 F3
7 budd-chiari syndrome 32.7 SERPINC1 JAK2 FGB F5 F3 F2
8 heparin-induced thrombocytopenia 32.7 SERPINC1 F3
9 sagittal sinus thrombosis 32.7 THBD SERPINC1 PLG JAK2 F5 F3
10 carotid artery thrombosis 32.6 SERPINE1 SERPINC1 PLG PLAT GP1BA F3
11 antiphospholipid syndrome 32.6 THBD SERPINE1 SERPINC1 PLAT F5 F3
12 intracranial sinus thrombosis 32.5 SERPINC1 PLG F3 F2
13 protein s deficiency 32.5 THBD SERPINC1 PROS1 PROC F5 F3
14 cerebral sinovenous thrombosis 32.4 PROS1 F5 F3 F2 APOH
15 thrombophilia due to activated protein c resistance 32.4 THBD SERPINE1 SERPINC1 PLG F5 F3
16 paroxysmal nocturnal hemoglobinuria 32.4 THBD SERPINC1 F2 CD55
17 polycythemia vera 32.4 THBD JAK2 F5 F2
18 post-thrombotic syndrome 32.4 SERPINE1 SERPINC1 PLG PLAT F5 F3
19 antithrombin iii deficiency 32.3 SERPINC1 PLG JAK2 F5 F2 APOH
20 essential thrombocythemia 32.3 THBD SERPINE1 SERPINC1 JAK2 GP1BA F3
21 protein c deficiency 32.3 THBD SERPINE1 SERPINC1 PROC HRG F9
22 thoracic outlet syndrome 32.3 SERPINC1 PLG F2
23 pulmonary embolism 32.3 THBD SERPINE1 SERPINC1 PROS1 PROC PLAT
24 prothrombin thrombophilia 32.3 HRG F2 F13A1
25 homocysteinemia 32.3 THBD SERPINE1 SERPINC1 F5 F2 APOH
26 may-thurner syndrome 32.2 F5 APOH
27 shwartzman phenomenon 32.2 SERPINA10 F3
28 chronic venous insufficiency 32.2 SERPINE1 PLAT F2
29 thrombotic microangiopathy 32.1 THBD F3
30 moyamoya disease 1 32.1 SERPINC1 PLG PLAT F3 F2
31 factor vii deficiency 32.0 SERPINC1 F9 F3 F2
32 hepatic veno-occlusive disease 32.0 THBD SERPINE1 SERPINC1 PLG PLAT F3
33 varicose veins 32.0 THBD SERPINC1 PLAT F5 F2
34 dysfibrinogenemia, congenital 32.0 THBD SERPIND1 SERPINC1 PLAT FGB F5
35 factor xii deficiency 32.0 SERPINC1 F9 F5 F3 APOH
36 factor v deficiency 32.0 F9 F5 F3 F2
37 thrombophilia 32.0 THBD SERPINE1 SERPIND1 SERPINC1 SERPINA10 PROS1
38 central retinal vein occlusion 31.9 SERPINC1 PLAT JAK2 F5 F3 F2
39 heparin cofactor ii deficiency 31.9 SERPIND1 SERPINC1 PLG
40 portal hypertension 31.9 JAK2 F3 F2
41 plasminogen activator inhibitor-1 deficiency 31.9 SERPINE1 PLAT
42 vascular disease 31.9 THBD SERPINE1 SERPINC1 PLG PLAT GP1BA
43 afibrinogenemia, congenital 31.8 SERPINE1 SERPINC1 PLG PLAT FGB F3
44 systemic lupus erythematosus 31.8 THBD SERPINE1 JAK2 F3 F2 CD55
45 cardiovascular system disease 31.8 THBD SERPINE1 SERPINC1 PLG PLAT F3
46 polycythemia 31.8 SERPINC1 JAK2 F5 F2
47 nephrotic syndrome 31.8 SERPINC1 PLG F9 F3 F2
48 venous insufficiency 31.7 SERPINE1 PLAT F5 F2
49 thrombocytosis 31.7 SERPINC1 JAK2 F3 F2
50 intracranial hypertension 31.7 SERPINE1 SERPINC1 F9 F5 F3 F2

Graphical network of the top 20 diseases related to Thrombosis:



Diseases related to Thrombosis

Symptoms & Phenotypes for Thrombosis

GenomeRNAi Phenotypes related to Thrombosis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-2 9.5 JAK2
2 Decreased viability GR00249-S 9.5 F13A1 F5 SERPINA10 SERPINE1
3 Decreased viability GR00381-A-1 9.5 PLAT SERPINA10
4 Decreased viability GR00381-A-2 9.5 SERPINA10
5 Decreased viability GR00381-A-3 9.5 SERPINA10
6 Decreased viability GR00386-A-1 9.5 GP1BA PROS1 SERPINA10
7 Decreased viability GR00402-S-2 9.5 FGB HRG SERPINA10

MGI Mouse Phenotypes related to Thrombosis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.38 F13A1 F2 F3 F5 F9 FGB
2 homeostasis/metabolism MP:0005376 10.38 APOH CD55 F13A1 F2 F3 F5
3 hematopoietic system MP:0005397 10.31 CD55 F13A1 F3 F9 FGB GP1BA
4 embryo MP:0005380 10.11 F2 F3 F5 F9 FGB JAK2
5 immune system MP:0005387 10.11 CD55 F2 F3 F9 JAK2 PLAT
6 mortality/aging MP:0010768 10.11 APOH CD55 F13A1 F2 F3 F5
7 integument MP:0010771 10.02 F13A1 F2 F3 F5 JAK2 PLAT
8 liver/biliary system MP:0005370 9.91 F5 F9 JAK2 PLG PROC PROS1
9 muscle MP:0005369 9.56 CD55 F2 F3 PLAT PROC PROS1
10 respiratory system MP:0005388 9.28 F13A1 F2 F3 JAK2 PLAT PLG

Drugs & Therapeutics for Thrombosis

Drugs for Thrombosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 418)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Norethindrone Approved Phase 4 68-22-4 6230
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
Atorvastatin Approved Phase 4 134523-00-5 60823
4
Dydrogesterone Approved, Investigational, Withdrawn Phase 4 152-62-5 9051
5
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
6
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
7
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
8
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
9
Metformin Approved Phase 4 657-24-9 14219 4091
10
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
11
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
12
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
13
Abciximab Approved Phase 4 143653-53-6
14
Tirofiban Approved Phase 4 144494-65-5 60947
15
Polyestradiol phosphate Approved Phase 4 28014-46-2
16
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
17
Acetaminophen Approved Phase 4 103-90-2 1983
18
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
19
fluindione Approved, Investigational Phase 4 957-56-2
20
Phenindione Approved, Investigational Phase 4 83-12-5 4760
21
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
22
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
23
Taurolidine Approved, Investigational Phase 4 19388-87-5
24
Glimepiride Approved Phase 4 93479-97-1 3476
25
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
26
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
27
Liraglutide Approved Phase 4 204656-20-2 44147092
28
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
29
Racepinephrine Approved Phase 4 329-65-7 838
30 Orange Approved Phase 4
31
Edoxaban Approved Phase 4 480449-70-5
32
Nadroparin Approved, Investigational Phase 4
33
Dipyridamole Approved Phase 4 58-32-2 3108
34
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
35
Dronedarone Approved Phase 4 141626-36-0, 141625-93-6 154087
36
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
37
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
38
Warfarin Approved Phase 4 81-81-2 6691 54678486
39
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
40
Lenvatinib Approved, Investigational Phase 4 417716-92-8
41
Ticagrelor Approved Phase 4 274693-27-5 9871419
42
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
43
Rivaroxaban Approved Phase 4 366789-02-8
44
Apixaban Approved Phase 4 503612-47-3 10182969
45
Argatroban Approved, Investigational Phase 4 74863-84-6 152951
46
Desirudin Approved Phase 4 120993-53-5
47
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
48 Garlic Approved, Nutraceutical Phase 4 8008-99-9
49
Coumarin Experimental Phase 4 91-64-5 323
50
arachidonic acid Experimental Phase 4 506-32-1 444899

Interventional clinical trials:

(show top 50) (show all 1327)
# Name Status NCT ID Phase Drugs
1 Residual Vein Thrombosis Establishes the Optimal Duration of Low Molecular Weight Heparins in Cancer Patients With Deep Vein Thrombosis of the Lower Limbs Unknown status NCT00450645 Phase 4 low molecular weight heparin
2 Dose Effect of Tranexamic Acid on the Incidence of Deep Venous Thrombus in Cardiac Surgery With Cardiopulmonary Bypass Unknown status NCT03838328 Phase 4 Tranexamic Acid
3 Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis:A Zelen-design Multicenter Randomized Controlled Trial Unknown status NCT02630095 Phase 4 Nadroparin Calcium and Warfarin
4 Study of the OmniWave Endovascular System in Subjects With Lower and Upper Extremity Deep Vein Thrombosis - SONIC I Study Unknown status NCT00640731 Phase 4
5 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis (TWISTER) Unknown status NCT01252420 Phase 4 Enoxaparin
6 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
7 Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial Unknown status NCT01021488 Phase 4 Rosuvastatin 20mg/d for 14days;enoxaparin only
8 Reload of High Dose Atorvastatin for Preventing Deep Vein Thrombosis in Statin Users Undergoing Total Knee Replacement Arthroplasty: RE-STOP-DVT Study- A Prospective Randomized Controlled Trial Unknown status NCT01063426 Phase 4 High dose Atorvastatin+enoxaparin;Enoxaparin
9 Comparison of Ultra-low-dose Oral Versus Trans-dermal Hormone Therapy on Coagulation Activation and Metabolic Risk Factors for Cardiovascular Disease Unknown status NCT02264743 Phase 4 Femoston Conti;EVOREL® CONTI
10 Efficacy and Safety of Warfarin Anticoagulation for Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients With Hypersplenism After Laparoscopic Splenectomy Unknown status NCT02238444 Phase 4 Warfarin;Dipyridamole;Aspirin;Low Molecular Weight Heparin
11 A Zelen-design Randomized Controlled Trial of the Effect of Anticoagulation After Endoscopic Therapy in Cirrhotic Patients With Portal Vein Thrombosis Unknown status NCT02398357 Phase 4 Nadroparin Calcium and Warfarin
12 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
13 The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Patients With Venous Thromboembolism. Unknown status NCT03129555 Phase 4 Dabigatran Etexilate Oral Capsule;Rivaroxaban Oral Tablet;Edoxaban Oral Tablet;Apixaban Oral Tablet
14 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
15 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
16 Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients Unknown status NCT02933788 Phase 4 Cilostazol;Acetylsalicylic acid
17 Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
18 Rule Out Transcatheter Aortic Valve Thrombosis With Post Implantation Computed Tomography Unknown status NCT02826200 Phase 4 Acenocoumarol
19 Low Molecular Weight Heparin in Prevention of Recurrent Arteriovenous Graft Thrombosis in Chronic Hemodialysis Patients. Unknown status NCT01970280 Phase 4 Enoxaparin
20 PPARGC1β And CNTN4 Genotype as a Pharmacogenetic Assay of Thrombosis and Bleeding Risks - a Cross-Over Controlled Trial of Aspirin in Individuals at Increased Cardiovascular Risk. Unknown status NCT02970604 Phase 4 Aspirin
21 RCT Research: the Treatment of Hepatic Carcinoma With Portal Vein Branch Tumor Thrombosis (Resection or Sorafenib) Unknown status NCT03178656 Phase 4 Sorafenib
22 Impact of a Biological Glue (Evicel®) on the Peri Operative Bleeding in Total Knee Prothesis Surgery Unknown status NCT00983112 Phase 4 Human Fibrinogen and human thrombin (Evicel);Sodium Chlorure (Physiological saline)
23 a Comparative Study of Aspirin Either at Fixed Dose or at a Dose Titrated by Platlet Function Analyzer(PFA-100) vs Placebo in Primary Prevention of Vascular Access for Hemodialysis Unknown status NCT02055131 Phase 4 aspirin
24 Evaluation of the Potential Action of Coagulation Factors Concentrates in the Reversal of the Antithrombotic Action of New Oral Anticoagulants: Studies ex Vivo in Blood Samples From Healthy Volunteers Unknown status NCT01478282 Phase 4 Rivaroxaban;Dabigatran
25 Prolonged Hemodialysis Catheter Survival With Copolymer Coating and Rt-PA - PROCOPrt-PA Trial Unknown status NCT01670474 Phase 4 rt-PA (2mg/2mL) actilysis;rt-PA
26 Rapid P2Y12 Receptor Inhibition Attenuates Inflammatory Cell Infiltration in Thrombus Aspirated From the Infarct-related Artery in STEMI Patients: A Prospective Randomized Trial of Ticagrelor Versus Clopidogrel Unknown status NCT02639143 Phase 4 ticagrelor;Clopidogrel
27 Phase 4 Study of Postoperative Prostaglandin E1 in Head and Neck Microsurgery Unknown status NCT00733434 Phase 4 Prostaglandin E1
28 Thrombus Aspiration During Percutaneous Coronary Intervention in Acute Non-ST-elevation Myocardial Infarction Study (TAPAS II) Unknown status NCT01013038 Phase 4
29 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
30 Phase 4 Study of Primary Angioplasty Combined Distal Injection of Abciximab to Thrombus and Aspiration With Catheter Unknown status NCT01383785 Phase 4
31 Hepatic Resection Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Complicated by Portal Vein Tumor Thrombosis.A Prospective and Randomized Clinical Trial Unknown status NCT01350206 Phase 4
32 A Randomised Controlled Trial Comparing Bacteraemia Rates in Closed Luer Lock Access Devices(TEGO) With Standard Devices in the Outpatient Haemodialysis Population Unknown status NCT01082770 Phase 4
33 Taurolidine Citrate and Unfractionated Heparin Combination Versus Unfractionated Heparin Alone in Prevention of Inflammation in Hemodialysis Catheters. Unknown status NCT03539718 Phase 4 Taurolidine heparin;Heparin Sodium
34 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
35 Randomized, Crossover Study of the Antithrombotic Effects of Ticagrelor Plus Aspirin Versus Clopidogrel Plus Aspirin When Administered With Bivalirudin Completed NCT01642238 Phase 4 Ticagrelor + ASA + Bivalirudin;Clopidogrel + ASA + Bivalirudin
36 Can Treatment With Low Molecular Weight Heparin During Pregnancy With Intrauterine Growth Restriction Increase Birth Weight? Completed NCT01390051 Phase 4 Innohep (Tinzaparin);tinzaparin
37 Phase 4 Study of the Effect of Celecoxib on the Antiplatelet Effect of Aspirin and Clopidogrel Completed NCT00882388 Phase 4 aspirin;celecoxib;aspirin + celecoxib;aspirin + clopidogrel;aspirin + clopidogrel + celecoxib
38 The Effect of Erythropoietin on Platelet Activation Markers: a Prospective Study in Healthy Volunteers Completed NCT01392612 Phase 4 erythropoietin
39 TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement: the TIRATROP Study, a Randomized Controlled Trial Completed NCT02505399 Phase 4 ticagrelor;clopidogrel
40 Low Dose Aspirin and Statins for Primary Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus: A Randomized Double-blind Placebo-controlled Trial Completed NCT00371501 Phase 4 Rosuvastatin;placebo;aspirin;placebo
41 Randomised, Prospective Study of the Use of In-Line Filtration on the Reduction of Complication Rate in Critically Ill Children Completed NCT00209768 Phase 4
42 Antiplatelet Therapy Effect on Platelet Extracellular Vesicles in Acute Myocardial Infarction Completed NCT02931045 Phase 4 Ticagrelor;Clopidogrel
43 Stents Coated With the Biodegradable Polymer on Their Abluminal Faces and Elution of Sirolimus Versus Biolimus Elution for the Treatment of de Novo Coronary Lesions - Destiny Trial Completed NCT01856088 Phase 4
44 Anti-inflammatory Effects of Intracoronary and Intravenous Abciximab Administration During Primary Percutaneous Coronary Intervention.(Molecole di Adesione Nella Sindrome Coronarica Acuta Completed NCT01757457 Phase 4 Intracoronary administration of an abciximab bolus during primary PCI;Intravenous administration of an abciximab bolus during primary PCI
45 Safety and Efficacy of Peri-procedural Use of Tirofiban in Elective Percutaneous Coronary Intervention for Long Coronary Lesions With Overlapping Drug-Eluting Stent Completed NCT01498003 Phase 4 tirofiban;normal saline solution
46 The MAgnitude of Platelet Inhibition and the Pharmacokinetics of a 600 mg Loading Dose of Clopidogrel, in Different Patient CATegories (Stable Angina Versus Acute-coronary Syndromes Versus ST-elevated Myocardial Infarction). Completed NCT01012544 Phase 4 Clopidogrel
47 Treatment of Upper Extremity Deep-Vein Thrombosis Completed NCT00245856 Phase 4 Dalteparin sodium injection;Warfarin
48 Absence of Residual Vein Thrombosis After an Episode of Unprovoked Deep Vein Thrombosis: Short-Term Anticoagulation is Safe. Completed NCT00623987 Phase 4 warfarin accordingly INR value
49 Residual Vein Thrombosis (RVT) Establishes the Optimal Duration of Oral Anticoagulants After a First Episode of Deep Vein Thrombosis of the Lower Limbs Completed NCT00438230 Phase 4 Warfarin
50 Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants Completed NCT02720328 Phase 4

Search NIH Clinical Center for Thrombosis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Pentoxifylline

Cochrane evidence based reviews: thrombosis

Genetic Tests for Thrombosis

Genetic tests related to Thrombosis:

# Genetic test Affiliating Genes
1 Thrombosis 29

Anatomical Context for Thrombosis

MalaCards organs/tissues related to Thrombosis:

40
Endothelial, Kidney, Liver, Brain, Heart, Thyroid, Breast

Publications for Thrombosis

Articles related to Thrombosis:

(show top 50) (show all 31242)
# Title Authors PMID Year
1
Clinical experience with alteplase in the management of intracardiac and major cardiac vessels thrombosis in pediatrics: a case series. 54 61
20427940 2010
2
Increased expression of tissue factor and protease-activated receptor-1 does not correlate with thrombosis in human lung adenocarcinoma. 61 54
20445954 2010
3
P2Y12 or P2Y1 inhibitors reduce platelet deposition in a microfluidic model of thrombosis while apyrase lacks efficacy under flow conditions. 54 61
20473398 2010
4
Acute mesenteric and aortic thrombosis associated with antithrombin deficiency: a rare occurrence. 61 54
19932950 2010
5
The annexin A5-mediated pathogenic mechanism in the antiphospholipid syndrome: role in pregnancy losses and thrombosis. 54 61
20353989 2010
6
Persistency of low levels of anticardiolipin and anti-beta2 glycoprotein1 in thrombosis. 54 61
20206880 2010
7
Role of the platelet chemokine platelet factor 4 (PF4) in hemostasis and thrombosis. 54 61
20004006 2010
8
[Relationship of von Willebrand factor gene single-nucleotide polymorphism with thrombosis diseases]. 54 61
20416208 2010
9
Emerging roles of fibronectin in thrombosis. 54 61
20116835 2010
10
An approach to molecular imaging of atherosclerosis, thrombosis, and vascular inflammation using microparticles of iron oxide. 61 54
19883911 2010
11
Neuropilin-1 targeting photosensitization-induced early stages of thrombosis via tissue factor release. 54 61
20087632 2010
12
Low level of factor V is associated with development of deep-vein thrombosis in Japanese patients. 54 61
19497612 2010
13
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation. 61 54
19582452 2010
14
Continuous intraarterial thrombolysis for early hepatic artery thrombosis following liver transplantation: case report. 54 61
20034941 2010
15
JAK2 mutation and thrombosis in the myeloproliferative neoplasms. 61 54
20425393 2010
16
Human platelets produced in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice upon transplantation of human cord blood CD34(+) cells are functionally active in an ex vivo flow model of thrombosis. 54 61
19741191 2009
17
ABO blood groups and genetic risk factors for thrombosis in Croatian population. 61 54
20017223 2009
18
Thrombosis markers in hip versus knee arthroplasty: a pilot study. 61 54
20065366 2009
19
Time course of thrombosis and fibrinolysis in total knee arthroplasty with tourniquet application. Local versus systemic activations. 54 61
19067121 2009
20
Prevalence of factor V leiden mutation in patients with thrombosis in Tunisia. 61 54
20218141 2009
21
Study on the changes of thrombosis-associated factors in patients with coronary heart disease of turbidity-phlegm blocking syndrome. 54 61
19802536 2009
22
[Effects of sodium ozagrel in primary thrombocytosis combined with thrombosis]. 54 61
19840484 2009
23
Shear-induced global thrombosis test of native blood: pivotal role of ADP allows monitoring of P2Y12 antagonist therapy. 54 61
19476973 2009
24
Bilateral cavo-ilio-femoral thrombosis in an adolescent with transient anti-phospholipid antibodies and factor V heterozygous mutation: a case report. 61 54
19918549 2009
25
Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. 54 61
19660606 2009
26
[Study of the genetic markers of thrombosis in hypertensive patients of the native population in the Republic of Mordovia]. 54 61
19824427 2009
27
Locally applied recombinant plasmin results in effective thrombolysis in a porcine model of arteriovenous graft thrombosis. 61 54
19481472 2009
28
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. 61 54
19414836 2009
29
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: relationship with thrombosis occurrence and JAK2 V617F allele burden. 54 61
19105233 2009
30
Role of pulsatile perfusion with tissue plasminogen activator in deceased donor kidneys with extensive glomerular thrombosis. 54 61
19249467 2009
31
The 19-bp deletion of dihydrofolate reductase (DHFR), methylenetetrahydrofolate reductase (MTHFR) C677T, Factor V Leiden, prothrombin G20210A polymorphisms in cancer patients with and without thrombosis. 61 54
18682947 2009
32
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. 54 61
18954937 2008
33
High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). 54 61
18539899 2008
34
Role of the protein C pathway in the extraintestinal thrombosis associated with murine colitis. 61 54
18514072 2008
35
Acute effects of different alcoholic beverages on vascular endothelium, inflammatory markers and thrombosis fibrinolysis system. 61 54
18295937 2008
36
Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. 61 54
18375790 2008
37
Late onset thrombosis in a case of severe protein S deficiency due to compound heterozygosity for PROS1 mutations. 61 54
18433462 2008
38
Albumin therapy augments the effect of thrombolysis on local vascular dynamics in a rat model of arteriolar thrombosis: a two-photon laser-scanning microscopy study. 61 54
18323493 2008
39
The paradoxical association between inherited factor VII deficiency and venous thrombosis. 54 61
18282149 2008
40
Simultaneous subacute coronary drug-eluting stent thrombosis in two different vessels of a patient with factor V Leiden mutation. 61 54
18334899 2008
41
Platelet PlA2 Polymorphism and the risk for thrombosis in heparin-induced thrombocytopenia. 61 54
18208809 2008
42
IgG antibodies to plasminogen and their relationship to IgG anti-beta(2)-glycoprotein 1 antibodies and thrombosis. 54 61
17646899 2008
43
Impaired binding of thrombin to thrombomodulin is associated with risk of deep vein thrombosis. 61 54
18590927 2008
44
Tissue plasminogen activator to prevent central venous access device infections: a systematic review of central venous access catheter thrombosis, infection and thromboprophylaxis. 54 61
18005145 2008
45
Molecular analysis of factor V Leiden, factor V Hong Kong, factor II G20210A, methylenetetrahydrofolate reductase C677T, and A1298C mutations related to Turkish thrombosis patients. 54 61
17911197 2007
46
Hyperhomocysteinemia, deep vein thrombosis and vitamin B12 deficiency in a metformin-treated diabetic patient. 61 54
17908667 2007
47
ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis. 61 54
17608762 2007
48
Late drug-eluting stent thrombosis and erythropoietin: cause and effect? 54 61
17446131 2007
49
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. 61 54
17576867 2007
50
Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis. 54 61
17534796 2007